The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Translating academic-center data to community settings to improve the adoption of bispecifics
In this video, Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, discusses the need to bridge the gap between academic-center data and community settings to improve clinical practice. She highlights the importance of educating community oncologists on newer therapies, such as bispecific antibodies, and providing them with the necessary tools and support to operationalize these treatments, to ensure patients have access to effective therapies in earlier lines of treatment. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
